Kiran Mazumdar-Shaw

Founder at Biocon Ltd.

Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw

Founder at Biocon Ltd.

Overview
Career Highlights

Syngene International Ltd.
Biocon Ltd.
Biocon Foundation

RelSci Relationships

2976

Number of Boards

45

Birthday

03/23/1953

Age

68

Number of Awards

28

Estimated Net Worth

$2.1B

Relationships
RelSci Relationships are individuals Kiran Mazumdar-Shaw likely has professional access to. A relationship does not necessarily indicate a personal connection.

Vice Chairman at Biocon Ltd.

Relationship likelihood: Strong

Executive Chairman at Equillium, Inc.

Relationship likelihood: Strong

Chief Executive Officer, MD & Executive Director at Syngene International Ltd.

Relationship likelihood: Strong

Founder & Chairman at Narayana Hrudayalaya Ltd.

Relationship likelihood: Strong

Professor at University of Waterloo

Relationship likelihood: Strong

Co-Founder at Celsius Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Infosys Ltd.

Relationship likelihood: Strong

Managing Director, Biocon Biologics Limited at Biocon Ltd.

Relationship likelihood: Strong

Professional at Baines Peter Consulting

Relationship likelihood: Strong

Chief Executive Officer, Director & MD at Biocon Ltd.

Relationship likelihood: Strong

Paths to Kiran Mazumdar-Shaw
Potential Connections via
Relationship Science
You
Kiran Mazumdar-Shaw
Founder at Biocon Ltd.
Family Members
Family Member
Vice Chairman at Biocon Ltd.

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Family Member
Vice Chairman at Biocon Ltd.

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Spouse
Vice Chairman at Biocon Ltd.

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Spouse
Vice Chairman at Biocon Ltd.

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Family Member
Professor at University of Waterloo

University of Waterloo is home to world-changing research and inspired teaching. At the hub of a growing network of global partnerships, Waterloo will shape the future by building bridges with industry and between disciplines, institutions and communities.

Education
Master Brewer
Class of 1975

University of Ballarat is a management consulting firm serving the public and higher education sectors.

Bachelor's Degree in Zoology
Class of 1973

Bangalore University is located in the Garden City of Bangalore aptly hailed as the “I.T. Capital of India”, was established in July 1964 as an off shoot of the University of Mysore, primarily to include institutions of higher learning located in the metropolitan city of Bangalore and the districts of Bangalore, Kolar and Tumkur, which eventually became a separate university. Initially, the two premier colleges of the city, the Central College (CC) and the University Visvesvaraya College of Engineering (UVCE) formed the nucleus of Bangalore University.

Attendee
Class of 1968
Memberships
Member
2019 - Current

Founded in 1964, the National Academy of Engineering (NAE) is a private, independent, nonprofit institution that provides engineering leadership in service to the nation. The mission of the National Academy of Engineering is to advance the well-being of the nation by promoting a vibrant engineering profession and by marshalling the expertise and insights of eminent engineers to provide independent advice to the federal government on matters involving engineering and technology.

Member
Current

The Giving Pledge is a campaign to encourage the wealthiest people in the world to make a commitment to give most of their wealth to philanthropic causes. The campaign specifically focuses on billionaires and was made public in 2010 by Warren Buffett and Bill Gates. The Huffington Post reported in April 2012 that "81 billionaires committed to giving at least half of their fortunes to charity". As of July 2013, 113 billionaire individuals and couples and one family group have signed the pledge.

Career History
Founder
1993 - Current

Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. It is engaged providing contract research and manufacturing services. The firm’s services include discovery chemistry, discovery biology, safety assessment, large molecule development, chemical development, formulation development, stability studies, polymer research, integrated discovery and development, and clinical development. The company was founded on November 18, 1993 and is headquartered in Bangalore, India.

Founder
1978 - Current

Biocon, India's largest biotech company is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe. Biocon's key innovations include world's first Pichia based recombinant human Insulin, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon. Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets. Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 75 countries. As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market. Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene. Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle. With the successful commercial launch of its first anti-cancer drug and several promising discovery partnerships in the clinic, the Company remains committed to scaling new heights in frontier science and achieving new milestones in affordable medicine

Founder
Current
Boards & Committees
Director
Current

Biocon Pharma, Inc., part of Biocon Ltd., is a company headquartered in the United States that manufactures and distributes pharmaceutical products.

Director
Prior

Science Foundation Ireland funds oriented basic and applied research in the areas of science, technology, engineering, and mathematics (STEM). It promotes and supports the study of, education in, and engagement with STEM and promotes an awareness and understanding of the value of STEM to society. The company was founded in 1998 and is headquartered in Dublin, Ireland,.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$50K +
2017

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Investments
Details Hidden

Narayana Hrudayalaya Ltd. engages in the provision of medical and health care services. It also provides services in the areas of cardiac surgery, cardiology, diabetes and endocrinology, gastroenterology, general surgery, neurosciences, facial surgery, nephrology, obstetrics and gynecology, orthopedics, oncology, pediatrics, transplant, urology, and vascular surgery; and other specialty services, such as dental, dermatology, emergency medicine, ears, nose, and throat, family medicine, general medicine, and genetic. The company was founded by Devi Prasad Shetty on July 19, 2000 and is headquartered in Bangalore, India.

Details Hidden

Printline Media is a venture that publishes, ThePrint.in, a news, analysis, opinion and knowledge venture, launched in August 2017 by editor Shekhar Gupta. It focuses on politics and policy, government, and governance. Its leadership team includes India's most experienced and respected journalists with proven track records in the finest news organizations. The news organization is headquartered in New Delhi and is in the process of building a network across India because we believe in investing in investigative and questioning journalism.

Details Hidden

UE Lifesciences, Inc. develops and provides medical devices and equipment. Its products include Intelligent Breast Exam. The company was founded by Mihir Shah and Matthew Campisi in January 2009 and is headquartered in Philadelphia, PA.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
2020
Ernst & Young - World Entrepreneur of the Year
2019
Deakin University
Rank #973
2017
Forbes Magazine - The World's Billionaires
Events
Speaker
Singapore
2013 Wall Street Journal Unleashing Innovation Conference

Attendee
Gurgaon, CT, India
2012 World Economic Forum on India

From Deliberation to Transformation

Attendee
Ambience Island National Highway 8-Gurgaon , Haryana
2012 World Economic Forum on India

From Deliberation to Transformation

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Kiran Mazumdar-Shaw. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Kiran Mazumdar-Shaw's profile does not indicate a business or promotional relationship of any kind between RelSci and Kiran Mazumdar-Shaw.